Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2023 Financial Results
November 06, 2023 08:00 ET
|
Keros Therapeutics, Inc.
LEXINGTON, Mass., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and...
Keros Therapeutics to Present at the 65th American Society of Hematology Annual Meeting and Exposition
November 02, 2023 09:00 ET
|
Keros Therapeutics, Inc.
LEXINGTON, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel...
Keros Therapeutics Presents Preclinical Data from its KER-065 Program at the 28th International Annual Congress of the World Muscle Society
October 04, 2023 08:00 ET
|
Keros Therapeutics, Inc.
LEXINGTON, Mass., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel...
Keros Therapeutics to Present at Upcoming Healthcare Conferences
September 05, 2023 08:00 ET
|
Keros Therapeutics, Inc.
LEXINGTON, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel...
Keros Therapeutics Reports Recent Business Highlights and Second Quarter 2023 Financial Results
August 07, 2023 08:00 ET
|
Keros Therapeutics, Inc.
LEXINGTON, Mass., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and...
Corrected: Keros Therapeutics to Host Conference Call and Webcast to Provide an Overview of TROPOS, the KER-012 Phase 2 Clinical Trial in Patients with Pulmonary Arterial Hypertension
July 27, 2023 16:01 ET
|
Keros Therapeutics, Inc.
LEXINGTON, Mass., July 27, 2023 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS) is re-issuing this press release solely to correct inadvertent typographical errors. The...
Keros Therapeutics to Host Conference Call and Webcast to Provide an Overview of TROPOS, the KER-012 Phase 2 Clinical Trial in Patients with Pulmonary Arterial Hypertension
July 24, 2023 08:00 ET
|
Keros Therapeutics, Inc.
Keros Therapeutics announces U.S. Food and Drug Administration (“FDA”) has cleared its investigational new drug application to conduct a Phase 2 clinical trial of KER-012 in combination with...
Keros Therapeutics Announces Update to Participation at the Goldman Sachs 44th Annual Global Healthcare Conference
June 12, 2023 08:00 ET
|
Keros Therapeutics, Inc.
LEXINGTON, Mass., June 12, 2023 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and...
Keros Therapeutics Presents Clinical Trial and Preclinical Study Results from its KER-050 Program and Preclinical Data from its ALK2 Inhibitor Program at the 28th Annual Congress of the European Hematology Association
June 09, 2023 06:00 ET
|
Keros Therapeutics, Inc.
Keros Therapeutics will be hosting a conference call and webcast today, June 9, 2023, at 8:00 a.m. Eastern time, to provide an update on its hematology franchise. LEXINGTON, Mass., June 09, 2023 ...
Keros Therapeutics to Present at Goldman Sach’s 44th Annual Global Healthcare Conference
June 07, 2023 08:00 ET
|
Keros Therapeutics, Inc.
LEXINGTON, Mass., June 07, 2023 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and...